The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC

Name: The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC
Published: 2021
License: Public Domain

Guangdong Provincial People's Hospital · 2021

ClinicalTrials.gov · Datasets · License: Public Domain · 2021

Open Source ↗

immunotherapy triple-negative-breast-cancer

triple negative breast cancer, tnbc, neoadjuvant, immunotherapy, anti-angiogenesis, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC

Related documents